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soning (accidental or intentional) requires accurate assessment and prompt therapy.
The necessity to prevent cross contamination during the initial evaluation should be emphasized.
Early identiﬁcation of the involved toxin/s is crucial and the majority will be identiﬁed by a thor-
ough history and physical examination. An ABC-approach should be followed ensuring a protected
airway, adequate ventilation and hemodynamic stability. Supportive and symptomatic care remains
the cornerstone of treatment. A stepwise approach may be followed to decrease the bioavailability
of toxins. Indications, contra-indications, risks and dosage regimens are describe for decontamina-
tion procedures including both termination of topical exposures and decreasing exposure to
ingested toxins. Furthermore, procedures to increase the elimination of toxins and a short section
covering speciﬁc toxins and their antidotes are also included.
The aim of this commissioned review was to establish concise guidelines for the initial management
of the acutely poisoned patient in the Emergency Centre. The American Academy of Clinical
Toxicology and the European Association of Poisons Centres and Clinical Toxicologists are the. Box 19063, Tygerberg 7505,
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Formulary.
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PoisoningAbstract Patients empoisonne´s de fac¸on aigue¨ sont couramment rencontre´es dans les centres
d’urgence. L’intoxication aigue¨ (accidentelle ou intentionnelle) ne´cessite une e´valuation pre´cise et
un traitement rapide.
La ne´cessite´ de pre´venir la contamination croise´e lors de l’e´valuation initiale doit eˆtre souligne´.
L’identiﬁcation pre´coce de la toxine en cause/s est cruciale et la majorite´ seront identiﬁe´s par une
histoire et un examen physique. Un ABC approche devrait eˆtre suivie assurer des voies ae´riennes
prote´ge´es, une ventilation ade´quate et de la stabilite´ he´modynamique. Les soins de soutien et symp-
tomatique reste la pierre angulaire du traitement. Une approche progressive peut eˆtre suivie pour
re´duire la biodisponibilite´ des toxines. Indications, contre-indications, les risques et les re´gimes pos-
ologiques pour de´crire les proce´dures de de´contamination, y compris a` la fois la cessation de l’expo-
sition d’actualite´ et l’exposition a` des toxines inge´re´es diminue. En outre, les proce´dures
d’augmenter l’e´limination des toxines et une courte section portant sur les toxines spe´ciﬁques et
leurs antidotes sont e´galement inclus.
Le but de cette e´tude commande´e e´tait d’e´tablir des lignes directrices concises pour la gestion initiale
du patient empoisonne´s de fac¸on aigue¨ dans le Centre d’urgence. L’American Academy of Clinical
Toxicology et l’Association europe´enne des centres antipoison et de toxicologie clinique sont les
chefs de ﬁle internationaux dans le domaine de la toxicologie et les lignes directrices dans leurs
prises de position e´taient ge´ne´ralement suivies. La plupart des re´gimes posologiques selon le Formu-
laire des me´dicaments en Afrique du Sud.
ª 2011 African Federation for Emergency Medicine. Production and hosting by Elsevier B.V. All rights
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Acutely poisoned patients are very commonly encountered in
South Africa. The exposure may be accidental (e.g. medication
error, unsafe storage) or intentional (e.g. para-suicide, sub-
stance abuse). Virtually all known chemicals have the potential
to cause injury or death, if the exposure is large enough. The
critical factor is not whether a substance is poisonous or not,
but whether exposure to it poses a risk. The practical value
of knowing that a product is relatively non-toxic prevents
unnecessary healthcare visits, overtreatment and an inappro-
priate response that may cause panic.
There are limited statistics available in South Africa regard-
ing poisoning as the cause of death. In 2007, the 9th Annual
Report of the National Injury Mortality Surveillance System
(NIMSS) attributed 4% of deaths to poisoning, with a peak
in the 30–34 year age group.1
Poison Information Centre (PIC) statistics in the United
States of America show that, during 2008, more than 2.4 mil-
lion human exposures were logged by 61 PICs, of which 1315
were fatalities i.e. 8.2 exposures per thousand population with
a fatality rate of 0.05%.2 Since 1999 the National Poison Infor-
mation Service (NPIS) in the United Kingdom has provided
both a national telephone service as well as free access to an
internet database service (TOXBASE) for all professionals reg-
istered with the National Health Service. The implementation
of the TOXBASE system almost halved the call load to the
National Poison Information Service.3 South Africa does not
have a single national poison information service or a facility
for access to an online database.
There are currently three PICs in South Africa, answering
about 11,000 calls per annum (Personal communication: Dr.
DJH Veale; May 2010). Unpublished data from the Tygerberg
Poison Information Centre conﬁrm anecdotal reports of poor
initial medical management of poisoned patients in South Afri-
can medical facilities.Box 1 Compounds with a high inherent toxicity.The aim of this commissioned review is to establish concise
guidelines for the initial management of the acutely poisoned
patient in the Emergency Centre. The American Academy of
Clinical Toxicology and the European Association of Poisons
Centres and Clinical Toxicologists are the international leaders
in the ﬁeld of toxicology and the guidelines in their position
papers were generally followed. Most of the dosage regimes
are according to the South African Medicines Formulary
(SAMF) as this is the most accessible reference guide for South
African healthcare workers.Approach to the management of the poisoned patient
Acute poisoning requires accurate assessment and prompt
therapy. All patients must be thoroughly assessed and stabi-
lized from the start.
History
Attempts should be made to try to identify the speciﬁc poison
but this however must never delay life-saving supportive care.4
Therefore, while vital functions are being assessed and stabi-
lised, a proper history should be obtained. Important informa-
tion to be gained from the history for risk assessment includes
the nature of the poisonous substance, the degree of exposure
and the time since exposure.4 Poisons, including medicines,
may be divided into two broad categories:5
i. Poisons (and/or their metabolites) which directly cause
irreversible or slowly reversible structural or functional
damage to one or more organ systems.These are also considered to be compounds with a high
inherent toxicity (Box 1). Included in this category, are
substances causing delayed signiﬁcant symptoms and
signs (e.g. paracetamol).
ii. Poisons which do not cause tissue damage directly or
those which cause toxic effects that are rapidly and com-
pletely reversible.
Fortunately, most potential poisons fall in this category
and appropriate symptomatic and supportive care
during the acute phase will usually ensure complete
recovery.4When dealing with a suspected toxic exposure or poisoning,
one of the major priorities should therefore be to attempt to
identify agents with a high inherent toxicity as soon as possi-
ble.5 Early identiﬁcation will allow for timeous special decon-
tamination and antidotal procedures in order to avoid severe
or permanent tissue damage.5 It should be noted that patients
who have ingested poisons with a high inherent tissue-damag-
ing potential often present with severe and persistent gastroin-
testinal symptoms and signs.5
A history obtained from a poisoned patient is often unreli-
able.4–7 If possible, relatives and friends should also be ques-
tioned as they may have useful information as to what the
poison was. A special effort should be made to obtain a sample
of the poisonous substance and its relevant container. Pre-hos-
pital personnel should be instructed to collect these from the
scene.4 Examination of the suspected toxic substance or the
material ingested is crucial for rapid and positive identiﬁcation
of a poison.
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A detailed physical examination must be performed after the
initial stabilization of the patient. Critical assessment of signs
and symptoms will not only assist in determining the etiology,
but may also help to assess the severity of the patient’s condi-
tion.8 Serious poisonings are often characterised by severe and
persistent gastrointestinal symptoms and signs, hypo- or
hypertension, hyperthermia, cardiac dysrythmias, altered men-
tal status, seizures, hypoglycaemia, acid–base and electrolyte
disturbances as well as signs of liver and renal impairment.5
As most deaths due to poisoning are a result of respiratory
compromise; special attention should be given to the evalua-Table 1 Summary of four common toxidromes.
Toxidrome Common signs
Anticholinergic (antimuscarinic) Delirium
Dilated pupils
Seizures
Raised temperature
Dry ﬂushed skin
Tachycardia,
Dysrythmias
Myoclonus
Urinary retention
Decreased bowel sounds
Cholinergic (muscarinic and nicotinic
receptor stimulation)
Confusion
CNS depression
Miosis
Seizures
Muscle weakness (including
Diaphoresis
Salivation
Lacrimation
Bronchorrhoea
Pulmonary oedema
Brady-/tachycardia
Emesis
Gastro-intestinal cramping
Urinary/faecal incontinence
Muscle fasciculations
CNS depressants Decreased mental alertness
Miosis
Hyporeﬂexia
Hypothermia
Respiratory depression
Hypotension
Bradycardia
Decreased bowel sounds
Sympathetic nervous system stimulants Delirium
Delusions
Paranoia
Hyperreﬂexia
Seizures
Raised temperature
Mydriasis
Diaphoresis
Piloerection
Tachycardia (Brady – if pur
Hypertension
Dysrythmiastion of the respiratory system.5 When dealing with suspected
acute poisoning, other life-threatening causes of these presen-
tations must be considered and excluded.4 Dynamic changes
in vital signs may be useful in evaluating the patient’s response
to supportive or antidotal treatment.8
Recognition of a speciﬁc toxidrome (a constellation of signs
and symptoms associated with a speciﬁc poisoning) may some-
times assist in the identiﬁcation of the class of poisonous sub-
stance involved.8–10 Four common toxidromes are summarised
in Table 1. Toxidromes are useful when dealing with unidenti-
ﬁed toxic agents, but may be misleading in certain circum-
stances such as exposure to more than one poisonous
substance. The onset of toxic manifestations may also be de-Common causes
Antihistamines
Antiparkinsonian agents
Antipsychotics
Antispasmodics
Atropine
Cyclic antidepressants
Mydriatics
Plants e.g. Datura stramonium (‘‘malpitte’’)
Organophosphate and
Carbamate pesticides
respiratory muscles)
Amitraz
Barbiturates
Benzodiazepines
Clonidine
Ethanol
Opioids
Amphetamines
Cocaine
Decongestants
Ephedrine
Methamphetamines
Methylphenidate
Salbutamol
e a-agonist)
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rooms, organophosphates, paracetamol and vitamin K-depen-
dant anticoagulants.
The toxicology laboratory
Although a ‘‘toxicology screen’’ may be of value in the identi-
ﬁcation of poisonous substances, the majority of toxicology-re-
lated diagnoses and therapeutic decisions are made from the
history or clinical examination.4,9 The usefulness of a toxicol-
ogy laboratory is further limited by a prolonged turnaround
time and high costs involved to run such a specialised service.
Furthermore, the fact that established cut off levels of toxicity
have not been determined for many toxins makes the interpre-
tation of test results very difﬁcult.4 The timing of specimen col-
lection is also important. If collected too early or too late the
results may have little clinical correlation.4 The use of quanti-
tative blood tests should be limited to those drugs and toxins
where the speciﬁc blood level will either predict toxicity or
guide speciﬁc therapy.4 Examples of such drugs are listed in
Box 2.
A routine quantitative serum paracetamol level is recom-
mended for ingestions of an unknown drug for two reasons:
(i) paracetamol is available in many over-the-counter prepara-
tions and (ii) the onset of signiﬁcant symptoms and signs may
be delayed in paracetamol poisoning .6
A detailed urine analysis may disclose important clues con-
cerning the diagnosis of an overdosed patient. The presence of
calcium oxalate crystals may indicate ethylene glycol poisoning
whereas the pH and the colour of the urine may also helpful.4
However, the necessity for routine urine drug testing is
debatable and possibly of questionable assistance in the emer-
gency setting as supportive treatment remains the cornerstone
of the management of the poisoned patient.9 Furthermore,
these test results rarely affect any clinical management
decisions.9
Without understanding the limitations of toxicology screen-
ing tests, physicians may interpret the results incorrectly.5 If
none of the compounds for which the requested tests were de-Box 2 Toxic substances where a quantitative result of a blood or
urine test may alter clinical management.
Box 3 Poison Information Centres operating in South Africa.signed are identiﬁed, the test is reported as negative. Conse-
quently, a negative screening test does not imply that
poisoning has not occurred, but only that the compounds
tested for are not implicated in the poisoning.4,5,9 Further-
more, healthcare personnel need to be fully aware of the sensi-
tivity and speciﬁcity of the tests they are ordering, as these may
differ between different laboratories.9
Qualitative urine tests are available for ‘drugs of abuse’ and
the range of drugs tested for depends on the instrumentation
available to individual laboratories. Speciﬁc reagent kits are
purchased for each of the tests and the instrumentation used
dictates which kits can be used. Most laboratories (state and
private sector) are able to do these tests, depending on their
ﬁnancial resources. Point-of-care qualitative urine screening
kits have low sensitivities and should not be used (Personal
communication: Dr. DJH Veale, January 2010).
In most cases of poisoning, standard special investigations
(e.g. serum electrolytes, glucose, ECG, etc) are often more
rewarding for diagnostic purposes than a toxicology screen.5
Sources of information
Additional information and guidance regarding the identiﬁca-
tion and management of the poisoning can be obtained by con-
sulting a local PIC. The contact details and operational times
of the South African PICs are available in Box 3. The South
African Medicines Formulary (SAMF) is also a good reference
to use.11Management of the poisoned patient
Staff should be aware of the necessity of taking universal
measures to prevent cross contamination during the initial
evaluation, depending on the nature of the poison (e.g. orga-
nophosphates, cyanide).12 An ABC-approach should be fol-
lowed ensuring a protected airway, adequate ventilation and
hemodynamic stability.12 Supportive and symptomatic care re-
mains the cornerstone of treatment.4 The poisoned patient
should be kept under close observation with frequent re-eval-
uation of vital signs and level of consciousness.4
A stepwise approach to decrease the bioavailability of a
toxin is illustrated in Box 4.Decontamination procedures
Terminating topical exposures
Patients exposed to any form of cutaneous contact should have
their clothes removed if contaminated. The affected areas
should be well rinsed with tap water and then washed with
soap or shampoo if available.13 In the event of serious skin
damage (e.g. chemical burns) the affected areas should be
rinsed with water alone.
A chemical burn of the eye is one of only a few ophthalmo-
logical emergencies.14 One dose of a local anaesthetic eye drop
may be instilled into the affected eye to aid in examination and
irrigation, the lids everted and any solid particles swept out of
the fornices with a cotton bud.12 Copious irrigation with nor-
mal saline or tap water is of utmost importance and should be
initiated as soon as possible.14 The eye must be irrigated for at
least 20 min.14 Neutralization of an acid or alkali should never
be attempted as it will result in an exothermic reaction. All
Box 4 A stepwise approach to decrease the bioavailability of a toxin.
Box 5 High risk factors for further self harm.
74 D.J. van Hoving et al.chemical burns involving the eyes need to be evaluated by an
ophthalmologist as an emergent case.15
Decreasing exposure to ingested toxins
Patients who have ingested any irritant or corrosive substance
may drink small sips of water. This procedure may assist in
establishing if the patient is able to swallow or not. The total
volume of water should not exceed 125 ml, and this volume
should be reduced in children.16 No attempts should be made
to neutralize ingested acids or alkalis with other agents. In
addition to causing a potentially harmful exothermic reaction,
excessive carbon dioxide (CO2) will be released which may re-
sult in gastric distension and perforation. 16
Gastro-intestinal decontamination
The American Academy of Clinical Toxicology and the Euro-
pean Association of Poisons Centres and Clinical Toxicologists
do not recommend the routine use of gastric decontamination,
but advise that it may be considered in selected cases.17–21
Although controversial, healthcare practitioners must always
determine whether the beneﬁts outweigh the associated risks.4
Emesis. The use of syrup of ipecacuahna to induce vomiting is
no longer recommended for several reasons: it possesses inher-
ent toxicity if dosed incorrectly and can cause delayed and
protracted vomiting, which delays other decontamination
measures and oral treatment.17
However, emesis itself is a non-invasive physiological mech-
anism.17 In our experience, inducing emesis using the gag reﬂex
may be useful but is not always successful. Giving a glass of
water before pharyngeal stimulation may prove effective. In
the alert paediatric patient, emesis induced in this way is easier
and less traumatic to perform than gastric lavage, as well as
being more effective for removing large tablets and objects
such as moth balls. It must only be considered in patients pre-
senting within 1 h post ingestion. The patient should be given
no more than 250 ml of water to drink, followed by mechanical
stimulation of the pharynx.Induction of emesis is contra-indicated when corrosive sub-
stances, volatile hydrocarbons (e.g. parafﬁn, petrol) or central
nervous system stimulants have been ingested as well as in any
patient with a decreased level of consciousness.17
Gastric lavage. Gastric lavage should not be performed during
the routine management of poisoned patients.18 The serious
risks of this procedure usually outweigh the possible beneﬁts.18
It is unethical to use gastric lavage as a punitive measure.4
Gastric lavage is only indicated, if ever, in patients with a sus-
pected lethal overdose who present within one hour after inges-
tion.18 It is contra-indicated in patients with an unprotected
airway, after ingestion of corrosive substances or substances
with a high aspiration potential (such as hydrocarbons), and
those with pre-morbid conditions where a risk of gastro-intesti-
nal tract bleeding is present.18 Serious risks of the procedure
include hypoxia, pharyngeal perforation, laryngospasm, aspira-
tion pneumonitis, gastro-intestinal tract perforation, ﬂuid and
electrolyte disturbances and dysrythmias.18
In order to perform a gastric lavage effectively, the correct
bore orogastric tube needs to be used. A large bore 36–40
French gauge tube (external diameter 12–13.3 mm) should be
used for adults and 24–28 French gauge tube (diameter 7.8–
9.3 mm) in children.18
Single dose activated charcoal. Activated charcoal (due to its
large surface area) adsorbs a signiﬁcant amount of poisonous
Clinical Review: Emergency management of acute poisoning 75substance in the gastrointestinal tract.19 Currently there are
limited studies to guide the use of single dose activated charcoal
and there is no evidence that it improves clinical outcomes.19
As with other decontamination measures, the administra-
tion of activated charcoal should not be routinely used in the
management of poisoned patients.4 It may be considered in
any patient who ingested a potentially toxic amount of a poi-
son, which is known to adsorb to charcoal, up to one hour
post ingestion.19 Administration after 1 h of ingestion remains
controversial.19
Box 5 lists the toxins that are not adsorbed by activated
charcoal.19,21 Administration of activated charcoal is contra-
indicated in patients with an unprotected airway, patients with
a risk of gastrointestinal obstruction and where its use will in-
crease the possibility of aspiration.19
The optimal dose of activated charcoal is unknown, but a
recommended dose is 1–1.5 g/kg of powder.19 This dose must
be adapted for the paediatric patient and 0.5–1 g/kg is recom-
mended.19 As a guide, a tablespoon of powder equals about
3.5–6 g. Tablets and capsules containing activated charcoal
are unsuitable. The slurry of activated charcoal is ideally pre-
pared by mixing the required dose with water in the proportion
of 8ml of water to 1g of charcoal, e.g. 50 g of powder in 400 ml
water.16,22 The slurry must be swallowed within a 30 min time
frame to be most effective.19 It should be administered via a
naso-gastric tube in patients who refuse to drink the slurry.19
The appearance of the slurry can be disguised by pouring it
into an empty cool drink can to make it more attractive for
children to drink. Adding cola may also help to disguise the
taste.23
Whole bowel irrigation. Whole bowel irrigation (WBI) involves
the oral administration of a large volume of an iso-osmotic
polyethylene glycol electrolyte solution in order to reduce drug
absorption by rapid mechanical cleansing of the entire gastro-
intestinal tract.20 It does not usually affect the ﬂuid or electro-
lyte balance.20 There is no conclusive evidence that the outcome
of poisoned patients is improved using this method.20 It may be
considered after ingestion of the following substances:
Iron or heavy metals
Sustained-released or enteric-coated drug formulations
Packets of illicit drugs (‘‘body-packers’’)20
Contra-indications include bowel obstruction, perforation
or ileus; haemodynamically unstable patients and patients with
unprotected airways.20
The iso-osmotic polyethylene glycol electrolyte solution is
best administered via a naso-gastric tube. The recommended
dosage is:
1500–2000 ml/h (adults and adolescents)
1000 ml/h (6–12years)
500 ml/h (9 months–6 yrs)
Administration of this solution should be continued until
the rectal efﬂuent is clear.20
Increasing elimination
Increasing the elimination of the toxin can be accomplished in
three different ways.Multi-dose activated charcoal (Gut dialysis)
The theoretical beneﬁt of multi-dose activated charcoal
(MDAC) is to interrupt the entero-enteric and entero-hepatic
circulation of drugs.21 The role of MDAC in improving mor-
bidity and mortality in the poisoned patient is still unclear.21
The optimal dosage regimen has not yet been clearly estab-
lished. Expert opinion suggests that MDAC should only be
considered in patients presenting with a potentially lethal dose
of carbamazapine, phenobarbitone, theophylline, dapsone or
quinine.21 It should not be used in patients who are unable
to protect their airways or in patients with gastrointestinal
obstruction.21
After an initial loading dose of 50 g activated charcoal in
400 ml water, repeat dosages (a slurry of 25 g every two hours
or 50 g every 4 h) is administered, preferably via naso-gastric
tube.16 The dosage should be reduced to 0.5 g/kg every two
hours or 1 g/kg every four hours in children (1–12 yrs). This
dosage regime should be continued until the patient’s clinical
condition improves and laboratory parameters or blood levels
(if available) decrease.21 The concurrent administration of
cathartics (e.g. sorbitol) is not recommended and could
result in ﬂuid and electrolyte imbalances, particularly in
children.21
The use of MDAC is relatively free from serious adverse ef-
fects. However, aspiration, constipation, impaction and
obstruction may occur and the patient should therefore be
evaluated frequently for ability to protect the airway and evi-
dence of decreased peristalsis or obstruction. 16,21
Urine alkalinisation
Intravenous sodium bicarbonate is administered to raise the
pH of urine. The rise in urinary pH increases the ionization
of drugs which are weak acids (e.g. salicylates). This effect re-
duces re-absorption in the renal tubules (ion-trapping).24
Urine alkalinisation is the ﬁrst line treatment for patients
with acute salicylate poisoning unless signs of neurotoxicity
are present (in which case haemodialysis becomes the treat-
ment of choice).24 Other possible indications include pheno-
barbitone, ﬂuoride or methotrexate poisoning.24 An initial
bolus of intravenous sodium bicarbonate (1 m Eq/kg) is
administered and additional boluses can be given there is no
clinical improvement.24 Although many toxicology books ad-
vise to maintain urine pH between 7.5 and 8.5, we found it
to be extremely difﬁcult to achieve in practice; furthermore,
there is the potential of overdosing the patient with sodium
bicarbonate.
Compromised renal function is a contraindication for urine
alkalinisation, and extreme care should also be taken in patients
with signiﬁcant pre-existing heart disease.24 The administration
of bicarbonate may lead to alkalaemia and hypokalaemia
(easily corrected with potassium supplementation).24
Clinical improvement and a decrease in blood drug levels
are indications for the discontinuation of alkalinisation of
the urine.24
Extracorporeal elimination
The removal of toxins by extracorporeal techniques such as
haemodialysis, haemoﬁltration and haemoperfusion is indi-
cated for only a small select group of poisons.25 Agents with
low protein binding, a low volume of distribution and a low
molecular weight are ideally eliminated using extracorporeal
techniques.25 Haemodialysis may be indicated in poisoning
Table 2 Antidotes and their public sector availability
Indication Antidote Availability in SA
Anticholinergics Physostigmine Not available
Arsenic, Lead, Mercury BAL (Dimercaprol) Not available
DMSA (Succimer) Not available
D-Penicillamine Limited availabilitya
Benzodiazepines Flumazenil Available
B-blockers Glucagon Available
Insulin and Glucose Available
Ca+ channel blockers Calcium Available
Glucagon Available
Insulin and Glucose Available
Cyanide Nitrite/sodium thiosulphate Available
regimen (Tripac-Cyano)
Dicobalt edetate Not available
Hydroxocobalamin Not available
Digoxin and cardiac glycosides Digoxin-speciﬁc Fab fragments Not availableb
Ethylene glycol Fomepizole Not available
Pyridoxine IV not available
Thiamine Available
Hydroﬂuoric acid Calcium gluconate Available
Iron Desferrioximine Available
Isoniazid Pyridoxine IV not available
Methanol Folic acid Available
Leucovorin Available
Ethanol Available
Oxidants (Methaemoglobin-forming agents) Methylene blue Short supply
Opioids Naloxone Available
Organophosphates and carbamates Atropine Available
Obidoxime Not availableb
Paracetamol N-acetylcysteine (IV and oral)2 Limited availabilitya
a Restricted stocks available, approval required from the Medicines Control Council.
b Still awaiting approval from the Medicines Control Council.
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ethylene glycol) and theophylline.25 The decision to use extra-
corporeal techniques must be made in consultation with a
nephrologist.25
Antidotes
Despite popular misconceptions, the administration of an anti-
dote is indicated in only the minority of poisoning cases.4 Basic
supportive and symptomatic measures might be all that is
needed with the possible addition of gastric decontamination
or methods to increase elimination.10
The administration of an antidote must only be considered
if the identity of the toxin has been conﬁrmed.4 The clinician
should be aware of the speciﬁc indications and contra-indica-
tions associated with the administration of the antidote.10
Table 2 lists the most common antidotes, possible indications
and current availability in South Africa (Personal communica-
tion: Dr. DJH Veale; December 2010). The availability of cer-
tain antidotes remains a problem in the South African public
healthcare sector and treating physicians should focus on pro-
viding optimal supportive care.26
Pearls and pitfalls of managing poisonings and respective
antidotes
Paracetamol. Paracetamol is the most common medicinal
overdose reported to PICs.27 The Rumack–Matthew nomo-gram can be used for predicting the potential for hepatotoxic-
ity and serves as a guide to whether antidotal therapy is
necessary.28 Interpretation of the nomogram is meaningless
in chronic ingestions or for blood levels drawn less than 4 h
post ingestion or 24 h post ingestion. Patients that are mal-
nourished or have induced cytochrome p-450 enzymes (e.g.
alcoholics or those taking enzyme-inducing drugs concur-
rently) are regarded at high risk for development of hepatotox-
icity and the lower ‘‘high risk’’ treatment line should be used as
the guide to the necessity for antidote administration.27 N-ace-
tylcysteine remains the cornerstone of therapy and can be
administered intravenously or orally.29 Superiority of N-ace-
tylcysteine to methionine is unclear, but N-acetylcysteine
seems superior to other antidotes (dimercaprol, carbocisteine,
cysteamine).30 Prolonged treatment with N-acetylcysteine for
2–3 days may be of beneﬁt in patients who are seriously poi-
soned and where antidotal therapy was started late.11
Opioids. Opioid poisoning may be reversed with naloxone, an
opioid receptor antagonist. The potential for precipitating
acute withdrawal in addicts is often detrimental and unpredict-
able; therefore the goal should not be complete arousal, but just
enough to alleviate respiratory depression.31 Administration of
naloxone should be via the intravenous route in order to facil-
itate better dose titration. Patients should be monitored contin-
uously as the half-life of naloxone is very short in comparison
to that of the opioid drugs and resedation often occurs.31
Box 6 High risk factors for further self harm.
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insecticides). Atropine is used to control the excessive musca-
rinic receptor stimulation. Different treatment regimes exist,32
but we suggest boluses of 0.05 mg/kg (max 4 mg) every 15 min
until control of excessive pulmonary secretions is evident.11
Large doses of atropine might be needed. Maintenance therapy
of atropine (intermittent or continuous infusions) may be given
at a rate of 0.05 mg/kg/h; titrate as needed using lung sounds
and oxygenation as endpoints.11 Tachycardia is not a contra-
indication for atropine but a urinary catheter should be in-
serted to prevent urinary retention. As the patient improves,
the atropine dose should be tapered off slowly over at least
24 h with close observation as rebound effects of the poisoning
may occur.11
The addition of glycopyrrolate (which does not cross the
blood brain barrier) to the atropine regimen can be considered
when atropine-induced CNS toxicity becomes evident but the
use of atropine is still indicated.33 Repeated intravenous doses
(1–2 mg in adults and 0.025 mg/kg in children) may be re-
quired as needed.33
Oximes (acetylcholinesterase reactivators such as pralidox-
ime and obidoxime) are also used in the treatment of acute
organophosphate poisoning, but current evidence is insufﬁ-
cient to indicate whether they are harmful or beneﬁcial.34
However, these drugs are not currently available in South
Africa.26
Benzodiazepines. Flumazenil (a benzodiazepine antagonist) is
only indicated in patients with marked respiratory depression
or deep coma e.g. in small children, the elderly and patients
with obstructive airway diseases.11 Extreme care should be ta-
ken in benzodiazepine-dependent patients and in patients with
a history of epilepsy. Flumazenil is contraindicated in co-inges-
tions of pro-convulsant drugs or tricyclic antidepressants.35
Resedation may occur after reversal, therefore patients should
be observed carefully.9
Tricyclic antidepressants. Because of the strong protein binding
and large volume of distribution of the tricyclic antidepressants,
urinary alkalinisation, dialysis or haemoperfusion are ineffec-
tive in the management of poisoning.11 Alkalinisation with so-
dium bicarbonate is of beneﬁt in convulsing patients and
those with signs of cardiotoxicity (ventricular dysrhythmias,
QRS duration greater than 0.10 s) and in adequately hydrated
patients with persistent hypotension.11,36 Benzodiazepines are
used to treat seizures.11Disposition
Any patient with a suspected poisoning should be admitted to
a medical facility for observation.
Patients with intentional self poisoning should undergo a
risk assessment for further self harm before discharge. High
risk factors (Box 6) should prompt the involvement of the psy-
chiatric team for a full psychiatric evaluation.37 These patients
should always be discharged in the care of a responsible
adult.37 Social support must also be offered to substance abuse
patients. This includes assistance with rehabilitation.Conclusion
This document proposes concise guidelines for the initial man-
agement of the acutely poisoned patient in the Emergency
Centre. The history and physical examination are important
in the identiﬁcation of the toxin/s involved. Supportive and
symptomatic care remains the mainstay of treatment in poi-
soning cases. A stepwise approach may be followed to decrease
the bioavailability of toxins.References
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